Additionally, uBCOs exhibited the expression of designated tumor stem-cell markers, in detail, CD24 and CD44, further highlighting their potential for studying BC stem cells and their capacity to expansion, as well as their responses to systemic anti-cancer agents in BC [31]. This evidence concerns the gene CD44 and breast cancer.